Stockscreener 앱 받기
19.95
0.30%
0.06
시간 외 거래:
19.95
전일 마감가:
$19.89
열려 있는:
$20.01
하루 거래량:
2.57M
Relative Volume:
1.45
시가총액:
$3.44B
수익:
$1.10B
순이익/손실:
$375.65M
주가수익비율:
9.0835
EPS:
2.1963
순현금흐름:
$113.59M
1주 성능:
-3.53%
1개월 성능:
-31.04%
6개월 성능:
-10.14%
1년 성능:
-6.69%
1일 변동 폭
$19.88
$20.24
1주일 범위
$19.59
$20.70
52주 변동 폭
$19.59
$30.96
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
19.95 | 3.56B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-02-23 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Acadia Pharmaceuticals stock hits 52-week low at $19.66 - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance Australia
How (ACAD) Movements Inform Risk Allocation Models - Stock Traders Daily
Acadia Pharmaceuticals Inc. (ACAD) stock price, news, quote and history - uk.finance.yahoo.com
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Yahoo Finance
Acadia debuts 63,000 sq. ft. Princeton office, biopharma hub designed by Ware Malcomb - Real Estate NJ
Acadia Pharmaceuticals (ACAD) Secures USPTO Notice of Allowance for Rett Syndrome Patent - GuruFocus
Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent - Yahoo Finance
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - Yahoo Finance
Acadia Pharmaceuticals stock price target lowered to $33 by H.C. Wainwright - Investing.com Canada
Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push - Simply Wall Street
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - 기업경제뉴스
Acadia Pharmaceuticals (ACAD) Shares Drop After Phase 2 RADIANT Study Results - GuruFocus
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) - Seeking Alpha
Acadia push in ADP still alive after near miss in phase II - BioWorld News
Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says - Yahoo Finance
ACAD Maintains Buy Rating -- Price Target Lowered to $33.00 by HC Wainwright - GuruFocus
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal - Yahoo Finance
Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss - Yahoo Finance
ACADIA Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co. - Moomoo
HC Wainwright & Co. maintains Buy rating on ACADIA Pharmaceuticals, $33 price target - TradingView
Needham cuts Acadia Pharmaceuticals stock price target on trial results By Investing.com - Investing.com Nigeria
Citizens maintains Market Outperform rating on ACADIA Pharmaceuticals, $33 price target - TradingView
Needham cuts Acadia Pharmaceuticals stock price target on trial results - Investing.com
ACAD Maintained by Needham -- Price Target Lowered to $35 - GuruFocus
Deutsche Bank Lowers Price Target on ACADIA Pharmaceuticals to $31 From $38, Keeps Buy Rating - Yahoo Finance
Citizens cuts Acadia Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Canada
Ware Malcomb says construction finished on Acadia Pharmaceuticals’ Princeton office - ROI-NJ
ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13% - Yahoo Finance
Acadia Pharmaceuticals stock tumbles on mixed trial results - Investing.com
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - TIKR.com
Acadia Alters Phase III Trials To Help Remlifanserin Succeed In Alzheimer’s Psychosis - insights.citeline.com
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20% - Yahoo Finance
Acadia Reports Phase 2 Data for Alzheimer’s Psychosis - TipRanks
Acadia reports Phase 3-enabling Phase 2 topline for remlifanserin in AD psychosis; 60 mg shows nominal CGI-S significance - TradingView
Biotech Rattled On Surprise Setback For Alzheimer's Drug - Investor's Business Daily
ACADIA Pharmaceuticals (ACAD) Drops 8.6% to $23.25 - AlphaStreet
BMO cuts Acadia Pharmaceuticals stock price target on trial miss By Investing.com - Investing.com Australia
ACADIA Pharma's price target cut after mixed Al... - Pluang
Goldman Sachs reiterates Acadia Pharmaceuticals stock Sell rating after trial miss - Investing.com Canada
TD Cowen reiterates Acadia Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease PsychosisSlideshow (NASDAQ:ACAD) 2026-09-24 - Seeking Alpha
Why Is Acadia Pharmaceuticals Stock Tumbling Today?ACADIA Pharmaceuticals (NASDAQ:ACAD) - benzinga.com
BMO cuts Acadia Pharmaceuticals stock price target on trial miss - Investing.com
Remlifanserin misses key goal in Alzheimer’s tr... - Pluang
Acadia shares drop 9% after mixed Phase 2 resul... - Pluang
Acadia Pharmaceuticals: Remlifanserin Is In Trouble (NASDAQ:ACAD) - Seeking Alpha
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Acadia Pharmaceuticals Inc 주식 (ACAD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 05 '26 |
Option Exercise |
17.84 |
5,849 |
104,346 |
73,677 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 06 '26 |
Sale |
29.22 |
14,292 |
417,604 |
67,828 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 05 '26 |
Sale |
29.00 |
5,849 |
169,638 |
67,828 |
0.05%
0.82%
자본화:
|
볼륨(24시간):